Valuation Metrics and Recent Changes
As of early April 2026, Abbott India’s price-to-earnings (P/E) ratio stands at 35.78, a figure that remains elevated compared to many of its pharmaceutical peers but has moderated enough to warrant a downgrade in its valuation grade from 'very expensive' to 'expensive'. The price-to-book value (P/BV) ratio is also high at 13.60, underscoring the premium investors continue to place on the company’s equity. Other valuation multiples such as EV to EBIT (30.28) and EV to EBITDA (29.05) further confirm the stock’s premium status.
Despite these lofty multiples, Abbott India maintains robust operational metrics, with a return on capital employed (ROCE) of 59.65% and a return on equity (ROE) of 38.00%, indicating efficient capital utilisation and strong profitability. The dividend yield, however, remains modest at 1.85%, which may temper income-focused investors’ enthusiasm.
Comparative Analysis with Sector Peers
When benchmarked against key competitors within the Pharmaceuticals & Biotechnology sector, Abbott India’s valuation appears stretched. For instance, Lupin and Glenmark Pharma are rated as 'very attractive' with P/E ratios of 21.09 and 24.36 respectively, and significantly lower EV/EBITDA multiples (13.71 and 13.27). Zydus Lifesciences and Biocon also present more attractive valuations, with P/E ratios of 16.91 and 62.12 respectively, though Biocon’s PEG ratio of 17.55 suggests growth expectations are priced in at a premium.
Conversely, companies like Mankind Pharma and Laurus Labs are classified as 'expensive' or 'very expensive', with P/E ratios of 45.01 and 67.63, indicating that Abbott India’s current valuation is more aligned with the higher end of the spectrum but not the most extreme.
Abbott India’s PEG ratio of 2.52, while elevated, is lower than Biocon’s but higher than Lupin’s 0.29, signalling that growth expectations relative to earnings are moderate but not overly optimistic.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Price Performance and Market Context
Abbott India’s stock price has shown mixed returns relative to the broader Sensex index. Over the past week, the stock declined by 1.00%, while the Sensex gained 3.71%. The one-month return for Abbott India was -6.14%, slightly worse than the Sensex’s -5.45%. Year-to-date, the stock has fallen 11.71%, marginally outperforming the Sensex’s 12.44% decline. Over a one-year horizon, Abbott India’s stock dropped 12.00%, contrasting with the Sensex’s positive 2.02% return.
Longer-term performance remains impressive, with a five-year return of 67.57% outperforming the Sensex’s 50.25%, and a remarkable ten-year return of 459.22% compared to the Sensex’s 202.27%. This track record highlights the company’s ability to generate substantial shareholder value over extended periods despite recent volatility.
Current Trading Range and Price Levels
The stock closed at ₹25,665 on 8 April 2026, down 0.95% from the previous close of ₹25,911. The day’s trading range was between ₹25,600 and ₹26,050. The 52-week high remains at ₹35,921.55, while the 52-week low is ₹25,600, indicating the stock is currently trading near its annual low, which may influence investor sentiment.
Investment Grade and Market Capitalisation
Abbott India is classified as a mid-cap company within the Pharmaceuticals & Biotechnology sector. Its MarketsMOJO Mojo Score stands at 46.0, reflecting a 'Sell' grade, a downgrade from the previous 'Hold' rating as of 9 March 2026. This shift signals a cautious stance from analysts, likely driven by the recent valuation adjustments and price performance.
Implications for Investors
The downgrade in valuation grade from 'very expensive' to 'expensive' suggests that while Abbott India remains a premium stock, the margin of overvaluation has narrowed. Investors should weigh the company’s strong profitability and historical returns against its stretched valuation multiples and recent price weakness.
Comparative analysis with peers reveals that several companies in the sector offer more attractive valuations, particularly Lupin and Glenmark Pharma, which combine lower P/E and EV/EBITDA ratios with appealing PEG ratios. This dynamic may prompt investors to consider reallocating capital towards these alternatives, especially given Abbott India’s modest dividend yield and recent underperformance relative to the Sensex.
Holding Abbott India Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Valuation Adjustment Reflects Market Realities
Abbott India Ltd’s recent valuation grade downgrade from 'very expensive' to 'expensive' encapsulates a subtle but meaningful shift in market perception. While the company continues to demonstrate strong operational metrics and a solid long-term track record, its premium multiples and recent price softness suggest that investors should approach with caution.
Given the availability of more attractively valued peers within the Pharmaceuticals & Biotechnology sector, investors may find better risk-reward opportunities elsewhere. The current environment calls for a balanced approach, factoring in Abbott India’s quality and growth prospects against its stretched valuation and relative underperformance.
Ultimately, the stock’s mid-cap status and recent Mojo Score downgrade to 'Sell' reinforce the need for careful portfolio consideration, especially for those seeking value and income in the pharmaceutical space.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
